X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (34) 34
index medicus (28) 28
hematology (26) 26
middle aged (26) 26
female (25) 25
male (23) 23
aged (22) 22
adult (18) 18
prognosis (18) 18
oncology (15) 15
antineoplastic combined chemotherapy protocols - therapeutic use (13) 13
cancer (12) 12
chemotherapy (12) 12
disease-free survival (11) 11
treatment outcome (11) 11
follow-up studies (10) 10
neoplasm staging (10) 10
survival (10) 10
aged, 80 and over (9) 9
disease (9) 9
leukemia, lymphocytic, chronic, b-cell - diagnosis (9) 9
leukemia, lymphocytic, chronic, b-cell - genetics (9) 9
chronic lymphocytic leukemia (8) 8
prospective studies (8) 8
antineoplastic combined chemotherapy protocols - administration & dosage (7) 7
care and treatment (7) 7
diagnosis (7) 7
kaplan-meier estimate (7) 7
non-hodgkins-lymphoma (7) 7
rituximab (7) 7
antineoplastic combined chemotherapy protocols - adverse effects (6) 6
cyclophosphamide - administration & dosage (6) 6
guidelines (6) 6
research (6) 6
therapy (6) 6
1st-line treatment (5) 5
abridged index medicus (5) 5
dosage and administration (5) 5
doxorubicin - administration & dosage (5) 5
drug administration schedule (5) 5
gene expression (5) 5
leukemia, lymphocytic, chronic, b-cell - metabolism (5) 5
leukemia, lymphocytic, chronic, b-cell - pathology (5) 5
lymphomas (5) 5
methotrexate (5) 5
mutation (5) 5
phase-ii (5) 5
survival analysis (5) 5
analysis (4) 4
biomarkers, tumor - genetics (4) 4
chronic lymphocytic leukaemia (4) 4
combined modality therapy (4) 4
cyclophosphamide - adverse effects (4) 4
disease progression (4) 4
elderly (4) 4
genetic aspects (4) 4
hematology, oncology and palliative medicine (4) 4
leukemia, lymphocytic, chronic, b-cell - therapy (4) 4
lymphocytosis - diagnosis (4) 4
lymphocytosis - genetics (4) 4
lymphoma, large b-cell, diffuse - drug therapy (4) 4
multiple-myeloma (4) 4
oncology, experimental (4) 4
patient outcomes (4) 4
patients (4) 4
remission induction (4) 4
response criteria (4) 4
retrospective studies (4) 4
transplantation (4) 4
vincristine - administration & dosage (4) 4
adolescent (3) 3
antibodies, monoclonal, murine-derived - administration & dosage (3) 3
antibodies, monoclonal, murine-derived - adverse effects (3) 3
b cells (3) 3
bendamustine (3) 3
bleomycin - administration & dosage (3) 3
cd38 expression (3) 3
central nervous system neoplasms - drug therapy (3) 3
central nervous system neoplasms - radiotherapy (3) 3
clinical trials (3) 3
combination (3) 3
cyclophosphamide - therapeutic use (3) 3
cytarabine (3) 3
diffuse large b-cell lymphoma (3) 3
doxorubicin - adverse effects (3) 3
doxorubicin - therapeutic use (3) 3
expression (3) 3
features (3) 3
flow-cytometry (3) 3
gene expression profiling (3) 3
genes (3) 3
immunoglobulin heavy chains - genetics (3) 3
immunoglobulins (3) 3
immunophenotype (3) 3
leukemia, lymphocytic, chronic, b-cell - immunology (3) 3
methotrexate - administration & dosage (3) 3
methotrexate - therapeutic use (3) 3
multivariate analysis (3) 3
natural-history (3) 3
non-hodgkin's lymphomas (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2009, Volume 374, Issue 9700, pp. 1512 - 1520
Summary Background Chemotherapy with high-dose methotrexate is the conventional approach to treat primary CNS lymphomas, but superiority of polychemotherapy... 
Internal Medicine | DEFERRED RADIOTHERAPY | MEDICINE, GENERAL & INTERNAL | B-CELL LYMPHOMA | INTERNATIONAL WORKSHOP | RESPONSE CRITERIA | EUROPEAN ORGANIZATION | CONSOLIDATING RADIOTHERAPY | NON-HODGKINS-LYMPHOMA | INITIAL TREATMENT | CENTRAL-NERVOUS-SYSTEM | CEREBROSPINAL-FLUID | Follow-Up Studies | Cytarabine - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytarabine - adverse effects | Methotrexate - therapeutic use | Lymphoma, Non-Hodgkin - radiotherapy | Cranial Irradiation - methods | Central Nervous System Neoplasms - radiotherapy | Adult | Lymphoma, Non-Hodgkin - drug therapy | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Logistic Models | Treatment Outcome | Combined Modality Therapy | Remission Induction | Methotrexate - adverse effects | Antimetabolites, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Aged | Lymphoma, Non-Hodgkin - mortality | Central Nervous System Neoplasms - drug therapy | Central Nervous System Neoplasms - mortality | Cytarabine | Patient outcomes | Central nervous system diseases | Dosage and administration | Lymphomas | Drug therapy, Combination | Methotrexate | Drug therapy | Data analysis | Disease | Monoclonal antibodies | Data collection | Radiation therapy | Patients | Tropical diseases | Index Medicus | Abridged Index Medicus
Journal Article
Current Oncology Reports, ISSN 1523-3790, 7/2015, Volume 17, Issue 7, pp. 1 - 9
Although the achievement of deep and long lasting remissions is a realistic goal of therapy in the fit patient with chronic lymphocytic leukemia (CLL), this... 
Comprehensive geriatric assessment | Oncology | Chronic lymphocytic leukemia | Unfit patients | Medicine & Public Health | Comorbidities | 1ST-LINE TREATMENT | FLUDARABINE PLUS CYCLOPHOSPHAMIDE | CANCER | PREVIOUSLY UNTREATED PATIENTS | PHASE-II TRIAL | OLDER PATIENTS | ONCOLOGY | RITUXIMAB | PROGRESSION-FREE | ELDERLY-PATIENTS | Comorbidity | Lymphomas | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2016, Volume 34, Issue 11, pp. 1175 - 1181
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2016, Volume 60, pp. 154 - 165
Journal Article
PLoS ONE, ISSN 1932-6203, 03/2015, Volume 10, Issue 3, p. e0118801
Journal Article
PLoS ONE, ISSN 1932-6203, 08/2011, Volume 6, Issue 8, p. e24313
Highly homologous B-cell receptors, characterized by non-random combinations of immunoglobulin heavy-chain variable (IGHV) genes and heavy-chain... 
GENE | IMMUNOGLOBULINS | BIOLOGY | SUBSETS | GENOMIC ABERRATIONS | PATTERNS | RISK | PATHOGENETIC IMPLICATIONS | ITALIAN MULTICENTER | PROGRESSION | ANTIGEN SELECTION | Complementarity Determining Regions - genetics | Prognosis | Humans | Gene Expression Regulation, Neoplastic | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Receptors, Antigen, B-Cell - metabolism | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Leukemia, Lymphocytic, Chronic, B-Cell - metabolism | Immunoglobulin Heavy Chains - metabolism | Receptors, Antigen, B-Cell - genetics | Cytogenetic Analysis | Neoplasm Staging | Complementarity Determining Regions - metabolism | Immunoglobulin Heavy Chains - genetics | Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis | Medical research | Chronic lymphocytic leukemia | Care and treatment | Medicine, Experimental | Development and progression | Research | B cells | Lymphocyte receptors | Trisomy | Working groups | Leukemia | Genes | Chains | Amino acids | Homology | ZAP-70 protein | Medical diagnosis | Clinical outcomes | Receptors | Clonal deletion | CD38 antigen | Deletion | Lesions | Chromosomes | Antigens | Immunoglobulins | Chronic lymphatic leukemia | Complementarity | Abnormalities | Medical treatment | Agent orange | Lymphatic leukemia | Gene expression | Patients | Lymphocytes B | Correlation analysis | Mutation | Cancer
Journal Article
British Journal of Haematology, ISSN 0007-1048, 02/2012, Volume 156, Issue 3, pp. 346 - 353
Summary This study investigated the clinical activity and toxicity of R‐HCVAD‐AM [rituximab plus HyperCVAD (R‐HCVAD) alternating with high‐dose cytarabine and... 
non‐Hodgkin lymphoma | clinical trials | prognostic factors | chemotherapy | monoclonal antibodies | Non-Hodgkin lymphoma | Clinical trials | Monoclonal antibodies | Chemotherapy | Prognostic factors | IMMUNOCHEMOTHERAPY | PROGRESSION-FREE SURVIVAL | SEQUENTIAL CHEMOTHERAPY | CVAD | non-Hodgkin lymphoma | REGIMENS | TRANSPLANTATION | THERAPY | RESCUE | UPDATE | HEMATOLOGY | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Cytarabine - adverse effects | Cyclophosphamide - adverse effects | Infection - etiology | Young Adult | Vincristine - administration & dosage | Adult | Lymphoma, Mantle-Cell - genetics | Doxorubicin - administration & dosage | Hematologic Diseases - chemically induced | Dexamethasone - administration & dosage | Drug Administration Schedule | Kaplan-Meier Estimate | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Treatment Outcome | Genetic Markers | Cytarabine - administration & dosage | Disease-Free Survival | Methotrexate - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - adverse effects | Methotrexate - administration & dosage | Aged | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Care and treatment | Stem cells | Dosage and administration | Transplantation | Non-Hodgkin's lymphomas | Methotrexate | Cancer | Autografts | cytarabine | Toxicity | mantle cell lymphoma | Survival | Age | rituximab | Index Medicus
Journal Article
British Journal of Haematology, ISSN 0007-1048, 10/2004, Volume 127, Issue 2, pp. 173 - 183
Journal Article
American Journal of Hematology, ISSN 0361-8609, 07/2014, Volume 89, Issue 7, pp. 743 - 750
Journal Article
Journal Article
British Journal of Haematology, ISSN 0007-1048, 06/2014, Volume 165, Issue 5, pp. 629 - 639
Journal Article
British Journal of Haematology, ISSN 0007-1048, 03/2016, Volume 172, Issue 6, pp. 879 - 888
Summary Survival rates for elderly Hodgkin Lymphoma (HL) have not improved substantially in recent years, mainly because of a lack of prospective randomized... 
Hodgkin Lymphoma | elderly | randomized study | Elderly | Randomized study | BENDAMUSTINE | EFFICACY | DOXORUBICIN | PHASE-II | VINBLASTINE | BLEOMYCIN | PREDNISONE | OLDER PATIENTS | DISEASE | ADRIAMYCIN | HEMATOLOGY | Procarbazine - administration & dosage | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Mitoxantrone - administration & dosage | Dacarbazine - therapeutic use | Hodgkin Disease - pathology | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - administration & dosage | Vinblastine - therapeutic use | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Bleomycin - therapeutic use | Vinblastine - adverse effects | Aged, 80 and over | Hodgkin Disease - drug therapy | Female | Mitoxantrone - adverse effects | Mitoxantrone - therapeutic use | Doxorubicin - administration & dosage | Dacarbazine - administration & dosage | Drug Administration Schedule | Kaplan-Meier Estimate | Treatment Outcome | Bleomycin - administration & dosage | Bleomycin - adverse effects | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Neoplasm Staging | Doxorubicin - adverse effects | Aged patients | Index Medicus
Journal Article